Lovastatin and Gemfibrozil in the Treatment of Type 2a and Type 2b Hyperlipoproteinemia

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1991 Jan 1

PMID 2044638

Citations 1

Authors

M J Tikkanen

J P Ojala

E Helve

Affiliations

Soon will be listed here.

Abstract

Subanalyses of previous multicenter studies comparing lovastatin and gemfibrozil were carried out to evaluate the merits of these agents in patients with different serum lipid phenotypes (type 2a and 2b hyperlipoproteinemia). Regardless of phenotype, lovastatin was more effective in lowering LDL-cholesterol, while gemfibrozil had a greater triglyceride-lowering and HDL-cholesterol-increasing effect. Patients with type 2a phenotype benefited (in terms of serum lipid pattern) more from lovastatin. In type 2b hyperlipoproteinemia, more patients taking lovastatin than gemfibrozil reached both treatment goals defined by the European Atherosclerosis Society, (LDL-cholesterol 4.0 mmol/l and triglycerides 2.3 mmol/l). In many patients these goals could not be met suggesting that multiple drug therapy may be indicated in part of the patients with type 2b hyperlipoproteinemia.

Citing Articles

Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.

Vazquez M, Zambon D, Hernandez Y, Adzet T, Merlos M, Ros E Br J Clin Pharmacol. 1998; 45(3):265-9.

PMID: 9517370 PMC: 1873371. DOI: 10.1046/j.1365-2125.1998.00672.x.

References

Grundy S, Vega G . Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med. 1987; 83(5B):9-20. DOI: 10.1016/0002-9343(87)90866-7. View

Tikkanen M, Helve E, Jaattela A, Kaarsalo E, Lehtonen A, Malbecq W . Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol. 1988; 62(15):35J-43J. DOI: 10.1016/0002-9149(88)90005-7. View

Tall A . Plasma lipid transfer proteins. J Lipid Res. 1986; 27(4):361-7. View

Schulzeck P, Bojanovski M, Jochim A, Canzler H, Bojanovski D . Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet. 1988; 1(8586):611-3. DOI: 10.1016/s0140-6736(88)91414-6. View

Ojala J, Helve E, Tikkanen M . Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study. Cardiology. 1990; 77 Suppl 4:39-49. DOI: 10.1159/000174682. View

Ginsberg H, Le N, Short M, Ramakrishnan R, Desnick R . Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest. 1987; 80(6):1692-7. PMC: 442441. DOI: 10.1172/JCI113259. View

NIKKILA E, Ylikahri R, HUTTUNEN J . Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Proc R Soc Med. 1976; 69 Suppl 2:58-63. PMC: 1864025. View

Helve E, Tikkanen M . Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. Atherosclerosis. 1988; 72(2-3):189-97. DOI: 10.1016/0021-9150(88)90080-9. View

. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart J. 1988; 9(5):571-600. View

10.

FRICK M, ELO O, Haapa K, Heinonen O, Heinsalmi P, Helo P . Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317(20):1237-45. DOI: 10.1056/NEJM198711123172001. View

11.

Tikkanen M, Bocanegra T, Walker J, Cook T . Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group. Am J Med. 1989; 87(4A):47S-53S. DOI: 10.1016/s0002-9343(89)80599-6. View